Loading...
IRMD logo
IRMD
IRADIMED

FDA Approval Will Unlock Broad MRI Market Expansion

Published
24 Sep 24
Updated
01 May 25
AnalystConsensusTarget's Fair Value
US$73.50
4.6% overvalued intrinsic discount
10 Sep
US$76.87
Loading
1Y
55.6%
7D
9.2%

Author's Valuation

US$73.54.6% overvalued intrinsic discount

AnalystConsensusTarget Fair Value

Narrative
Updates8

Shared on01 May 25
Fair value Increased 8.20%

Read more

Shared on23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on02 Apr 25
Fair value Increased 2.60%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on11 Mar 25
Fair value Decreased 6.75%

AnalystConsensusTarget has decreased revenue growth from 14.7% to 12.8%.

Read more